DOTmed January 16, 2025
Boston Scientific has announced a definitive agreement to acquire Bolt Medical, a developer of laser-based intravascular lithotripsy (IVL) technology for coronary and peripheral artery disease.
The acquisition, valued at approximately $443 million upfront for the 74% stake not already owned, includes potential milestone payments of up to $221 million. Boston Scientific already holds a 26% equity stake in Bolt Medical, having helped establish the company in 2019.
Bolt Medical’s IVL technology uses acoustic pressure waves to fracture calcium deposits within arteries, addressing complex calcified arterial disease through a minimally invasive approach. The Bolt IVL system, designed with visible, directional emitters for consistent energy delivery, complements Boston Scientific’s existing cardiovascular offerings.
“Intravascular lithotripsy therapy addresses a significant unmet need for patients...
Today's Sponsors
Today's Sponsor